{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:13:53Z","timestamp":1783678433010,"version":"3.55.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":97,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.100969","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T17:12:06Z","timestamp":1776186726000},"page":"100969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Upadacitinib Retreatment or Dose Escalation After Loss of Response in Ulcerative Colitis: Data From the Open-Label Extension of the U-ACTIVATE Study"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla","family":"Dubinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kujawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Dubcenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Ogholikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Marced","family":"Barrachina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2026.100969_bib1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/bmj.330.7492.644","article-title":"Monitoring in chronic disease: a rational approach","volume":"330","author":"Glasziou","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.gastha.2026.100969_bib2","first-page":"335","article-title":"Treatment de-escalation in patients with inflammatory bowel disease","volume":"15","author":"Israel","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.gastha.2026.100969_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5009\/gnl220070","article-title":"De-escalation of therapy in patients with quiescent inflammatory bowel disease","volume":"17","author":"Miyatani","year":"2023","journal-title":"Gut Liver"},{"key":"10.1016\/j.gastha.2026.100969_bib4","first-page":"213","article-title":"De-escalation of therapy for patients with inflammatory bowel disease","volume":"18","author":"Ungaro","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.100969_bib5","first-page":"612","article-title":"Restarting biologic agents after a drug holiday","volume":"15","author":"Rubin","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.gastha.2026.100969_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/17474124.2024.2412048","article-title":"Interrupting inflammatory bowel disease therapy: why, who, when and how to consider medication holidays","volume":"18","author":"St-Pierre","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.100969_bib7","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2026.100969_bib8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S2468-1253(23)00208-X","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.100969_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.100969_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/apt.17816","article-title":"Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis","volume":"59","author":"Panaccione","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2026.100969_bib12","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.100969_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2468-1253(25)00017-2","article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study","volume":"10","author":"Panaccione","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.100969_bib14","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/ecco-jcc\/jjab065","article-title":"Efficacy and safety of tofacitinib re-treatment for ulcerative colitis after treatment interruption: results from the OCTAVE clinical trials","volume":"15","author":"Pan\u00e9s","year":"2021","journal-title":"J Crohns Colitis"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:24:15Z","timestamp":1783675455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326000907"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100969","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Upadacitinib Retreatment or Dose Escalation After Loss of Response in Ulcerative Colitis: Data From the Open-Label Extension of the U-ACTIVATE Study","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"100969"}}